Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > This constant selling...........
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(548)
•••
Comment by Rumpl3StiltSkinon May 27, 2022 12:36pm
126 Views
Post# 34712483

RE:RE:RE:RE:RE:RE:RE:This constant selling...........

RE:RE:RE:RE:RE:RE:RE:This constant selling...........
Eoganacht wrote: But Hutchmed, Li Ka-shing's cancer drug company might...

Hutchmed was expecting FDA approval for their first anti-cancer drug in the US, surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumours. Instead they got a complete response letter from the FDA on May 2. Hutchmed had built a small US commercialization team in anticipation of approval. So now they have a US team in place but no approved drug to commercialize.

Rumpl3StiltSkin wrote: I think we will get AA early 2nd qtr 2023. Yes Laser. I think that is what they mean by commercial revenues. Selling 1433 to urologists in the US with an, conditionally, FDA approved product. They will likely need some partner for this as they don't currently have the resources to market distribute and manufacture all the different pieces of their ACT. At least not to Scale...




Excellent point Eoga! ;-)

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities